Tankyrases: structure, function and therapeutic implications in cancer. 2014

Teemu Haikarainen, and Stefan Krauss, and Lari Lehtio

Several cellular signaling pathways are regulated by ADP-ribosylation, a posttranslational modification catalyzed by members of the ARTD superfamily. Tankyrases are distinguishable from the rest of this family by their unique domain organization, notably the sterile alpha motif responsible for oligomerization and ankyrin repeats mediating protein-protein interactions. Tankyrases are involved in various cellular functions, such as telomere homeostasis, Wnt/β-catenin signaling, glucose metabolism, and cell cycle progression. In these processes, Tankyrases regulate the interactions and stability of target proteins by poly (ADP-ribosyl)ation. Modified proteins are subsequently recognized by the E3 ubiquitin ligase RNF146, poly-ubiquitinated and predominantly guided to 26S proteasomal degradation. Several small molecule inhibitors have been described for Tankyrases; they compete with the co-substrate NAD(+) for binding to the ARTD catalytic domain. The recent, highly potent and selective inhibitors possess several properties of lead compounds and can be used for proof-of-concept studies in cancer and other Tankyrase linked diseases.

UI MeSH Term Description Entries
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D038501 Tankyrases A group of telomere associated proteins that interact with TRF1 PROTEIN, contain ANKYRIN REPEATS and have poly(ADP-ribose) polymerase activity. Tankyrase,TRF-1 Interacting, Ankyrin-Related, ADP-Ribose Polymerases

Related Publications

Teemu Haikarainen, and Stefan Krauss, and Lari Lehtio
February 2006, Oncogene,
Teemu Haikarainen, and Stefan Krauss, and Lari Lehtio
December 2003, Acta dermatovenerologica Croatica : ADC,
Teemu Haikarainen, and Stefan Krauss, and Lari Lehtio
April 2019, Seminars in immunology,
Teemu Haikarainen, and Stefan Krauss, and Lari Lehtio
June 1987, Journal of the American Geriatrics Society,
Teemu Haikarainen, and Stefan Krauss, and Lari Lehtio
January 1995, Annual review of pharmacology and toxicology,
Teemu Haikarainen, and Stefan Krauss, and Lari Lehtio
April 2000, Annals of the New York Academy of Sciences,
Teemu Haikarainen, and Stefan Krauss, and Lari Lehtio
August 2023, Medical oncology (Northwood, London, England),
Teemu Haikarainen, and Stefan Krauss, and Lari Lehtio
October 2003, Current drug targets. CNS and neurological disorders,
Teemu Haikarainen, and Stefan Krauss, and Lari Lehtio
July 2006, Heart failure clinics,
Teemu Haikarainen, and Stefan Krauss, and Lari Lehtio
April 2022, International journal of molecular medicine,
Copied contents to your clipboard!